Selection of Antiepileptic Drugs in Adults

Neurologic Clinics

Volumn 27, Issue 4, 2009, Pages 967-992

  Stephen, Linda J ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Adults; Antiepileptic drug selection; Epilepsy; Seizures; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADULT; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ATAXIA; CLINICAL EXAMINATION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; EPILEPSY; FOCAL EPILEPSY; HUMAN; INCIDENCE; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; LIVER FAILURE; MYOCLONUS SEIZURE; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; REVIEW; TONIC CLONIC SEIZURE; VISUAL FIELD DEFECT;

ADULT; ANTICONVULSANTS; EPILEPSY; HUMANS;

EID: 70350159331     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.06.007     Document Type: Review

References (151)

1. Hauser W.A., Annegers J.F., and Rocca W.A. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 71 (1996) 576-586
2. SIGN Guideline 70. Diagnosis and management of epilepsy in adults. Scottish Intercollegiate Guidelines Network. Edinburgh. 2003. Available at:. www.sign.ac.uk Accessed April 2009
3. Dulac O., Leppik I.E., Chadwick D.W., et al. Starting and stopping treatment. In: Engel Jr. J., and Pedley T.A. (Eds). Epilepsy: a comprehensive textbook. 2nd edition (2008), Wolter Kluwer/Lippincott Williams and Wilkins, Philadelphia 1301-1309
4. Stephen L.J., and Brodie M.J. The management of a first seizure. Still a major debate. Special problems: adults and elderly. Epilepsia 49 Suppl 1 (2008) 45-49
5. Mohanraj R., Norrie J., Stephen L.J., et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 5 (2006) 481-487
6. National Institute for Clinical Excellence. Clinical guideline 20. The epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Available at: (2004). http://www.nice.org.uk/nicemedia/pdf/CG020NICEguideline.pdf Accessed April 2009
7. SIGN Guideline 81. Diagnosis and management of epilepsies in children and young people. Scottish Intercollegiate Guidelines Network. Edinburgh (2005). www.sign.ac.uk
8. American Academy of Neurology. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and of the American Epilepsy Society. 2004. Available at:. http://www.aesnet.org/go/practice/guidelines Accessed April 2009
9. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE Treatment Guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47 (2006) 1094-1120
10. Leppik I.E. Rational monotherapy for epilepsy. In: Brodie M.J., and Treiman D.M. (Eds). Modern management of epilepsy. Balliere's clinical neurology vol. 5 (1996), Balliere-Tindall, London 749-755 England
11. Brodie M.J., Chadwick D.W., Anhut H., et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 43 (2002) 993-1000
12. Sundqvist A., Tomson T., and Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit 21 (1998) 91-96
13. Elterman R.D., Shields W.D., Mansfield K.A., et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 57 (2001) 1416-1421
14. Liporace J.D., Sperling M.R., and Dichter M.A. Absence seizures and carbamazepine in adults. Epilepsia 35 (1994) 1026-1028
15. Duarte J., Sempere A.P., Cabezas M.C., et al. Postural myoclonus induced by phenytoin. Clin Neuropharmacol 19 (1996) 536-538
16. Ascapone J., Diedrich A., and DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 41 (2000) 479-481
17. Gelisse P., Genton P., Kuate C., et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 45 (2004) 1282-1286
18. Mikkelsen B., Berggreen P., Joensen P., et al. Clonazepam (Rivotril) and carbamazepine (Tegretol) in psychomotor epilepsy: a randomized multicenter trial. Epilepsia 22 (1981) 415-420
19. Ramsay R.E., Wilder B.J., Berger J.R., et al. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 33 (1983) 904-910
20. Mattson R.H., Cramer J.A., Collins J.F., et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313 (1985) 145-151
21. Dam M., Ekberg R., Løying Y., et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3 (1989) 70-76
22. Mattson R.H., Cramer J.A., and Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 327 (1992) 765-771
23. Richens A., Davidson D.L., Cartlidge N.E., et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 57 (1994) 682-687
24. Brodie M.J., Richens A., and Yuen A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. The UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 345 (1995) 476-479
25. Christie W., Kramer G., Vigonius U., et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26 (1997) 451-460
26. Bill P.A., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27 (1997) 195-204
27. Guerreiro M.M., Vigonius U., Pohlmann H., et al. A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27 (1997) 205-213
28. Chadwick D.W., Anhut H., Greiner M.J., et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures: International Gabapentin Monotherapy Study Group 945-77. Neurology 51 (1998) 1282-1288
29. Steiner T.J., Dellaportas C.I., Findley L.J., et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40 (1999) 601-607
30. Brodie M.J., Overstall P.W., and Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 37 (1999) 81-87
31. Chadwick D.W. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised DB study: Vigabatrin European Monotherapy Study Group. Lancet 354 (1999) 13-19
32. Privitera M.D., Brodie M.J., Mattson R.H., et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107 (2003) 165-175
33. Gilliam F.G., Veloso F., Bomhof M.A., et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 60 (2003) 196-202
34. Arroyo S., Dodson W.E., Privitera M.D., et al. A randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112 (2005) 214-222
35. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine and carbamazepine. Neurology 64 (2005) 1868-1873
36. Brodie M.J., Perucca E., Ryvlin P., et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
37. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
38. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1016-1026
39. Saetre E., Perucca E., Isojärvi J., et al. An international multicentre randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 48 (2007) 1292-1302
40. Shakir R.A., Johnson R.H., Lambie D.G., et al. Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia 22 (1981) 27-33
41. Turnbull D.M., Rawlins M.D., Weightman D., et al. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 45 (1982) 55-59
42. Turnbull D.M., Howel D., Rawlins M.D., et al. Which drug for the adult epileptic patient: phenytoin or valproate?. Br Med J 313 (1985) 145-151
43. Callaghan N., Kenny R.A., O'Neill B., et al. A prospective study between carbamazepine, phenytoin, and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 48 (1985) 639-644
44. Aikia M., Kalviainen R., Sivenius J., et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 11 (1992) 199-203
45. Placencia M., Sander J.W., Shorvon S.D., et al. Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Res 14 (1993) 237-244
46. Pulliainen V., and Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Epilepsia 36 (1995) 1195-1202
47. Heller A.J., Chesterman P., Elwes R.D., et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 57 (1995) 682-687
48. Kalviainen R., Aikia M., Saukkonen A.M., et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 52 (1995) 989-996
49. Reunanen M., Dam M., and Yuen A.W.C. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 345 (1996) 149-155
50. Brodie M.J., and Kwan P. Staged approach to epilepsy management. Neurology 58 Suppl 5 (2002) S2-S8
51. Marson A.G., Williamson P.R., Hutton J.L., et al. Carbamazepine versus valproate monotherapy for epilepsy (Cochrane Review). Cochrane Database Syst Rev 3 (2000). CD001030 doi:10.1002/14651858
52. Tudur Smith C., Marson A.G., and Williamson P.R. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 4 (2001). CD001769 doi:10.1002/14651858
53. Tudur Smith C., Marson A.G., and Williamson P.R. Carbamazepine versus phenobarbitone monotherapy for epilepsy. The Cochrane Database Syst Rev 1 (2003). CD001904 doi:10.1002/14651858
54. Taylor S., Tudur Smith C., Williamson P.R., et al. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2 (2003). CD002217 doi:10.1002/14651858
55. Posner E.B., Mohamed K., and Marson A.G. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 4 (2005). CD003032 doi:10.1002/14651858
56. Muller M., Marson A.G., and Williamson P.R. Oxcarbazepine versus phenytoin monotherapy. CD003615. The Cochrane Database Syst Rev 2 (2006) 10.1002/14651858
57. Gamble C.L., Williamson P.R., and Marson A.G. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev 1 (2006). CD001031 doi:10.1002/14651858
58. Pellock J.M., and Brodie M.J. Felbamate: an update. Epilepsia 38 (1997) 1261-1264
59. Willmore L.J., Abelson M.B., Ben-Menachem E., et al. Vigabatrin: 2008 update. Epilepsia 50 (2009) 163-173
60. Arif H., Buchbaum R., Weintraub D., et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68 (2007) 1701-1709
61. Hirsch L.J., Arif H., Nahm E.A., et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 71 (2008) 1527-1534
62. Man C.L.B., Kwan P., Baum L., et al. Association between HLA-B*1502 allele and antiepileptic drugs-induced cutaneous reactions in Han Chinese. Epilepsia 48 (2007) 1015-1018
63. Holmes L.B., Harvey E.A., Coull B.A., et al. The teratogenicity of antiepileptic drugs. N Engl J Med 344 (2001) 1132-1138
64. Tomson T., Perucca E., and Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 45 (2004) 1171-1175
65. Harden C., Meador K.J., Pennell P.B., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes. Epilepsia 50 (2009) 1237-1246
66. Meador K., Baker G., Browning N., et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360 (2009) 1597-1605
67. Morrow J., Russell A., Guthrie E., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77 (2006) 193-198
68. Dodrill C.B. Neuropsychological aspects of epilepsy. Psychiatr Clin North Am 15 (1992) 383-394
69. Camfield C.S., Chaplin S., Doyle A.B., et al. Side effects of phenobarbital in toddlers. J Pediatr 95 (1979) 361-365
70. Sulzbacher S., Farwell J.R., Temkin N., et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr 38 (1999) 387-394
71. Kwan P., and Brodie M.J. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45 (2004) 1141-1149
72. Gillham R.A., Williams N., Wiedmann K.D., et al. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg Psychiatry 51 (1988) 655-660
73. Craig I., and Tallis R. Impact of valproate and phenytoin on cognitive function in elderly people: results of a single-blind, randomized, comparative study. Epilepsia 35 (1994) 381-390
74. Prevey M.L., Delaney R.D., Cramer J.A., et al. Effect of valproate on cognitive functioning: comparison with carbamazepine. Arch Neurol 53 (1996) 1008-1016
75. Read C.L., Stephen L.J., Stolarek I.H., et al. Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure 7 (1998) 159-162
76. Kwan P., and Brodie M.J. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 357 (2001) 216-222
77. Mula M., Trimble M.R., Yuen A., et al. Psychiatric adverse events during levetiracetam therapy. Neurology 61 (2003) 704-708
78. Bootsma H.P.R., Ricker L., Diepman L., et al. Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 17 (2008) 19-26
79. Ben-Menachem E., Henriksen O., Dam M., et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37 (1996) 539-543
80. Huang C.-W., Pai M.-C., and Tsai J.-J. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry Clin Neurosci 62 (2008) 548-553
81. Geddes J.R., Calabrese J.R., and Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194 (2009) 4-9
82. Van der Loos M.L., Mulder P., Hartong G.H., et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychopharmacol 70 (2009) 223-231
83. Vernillo A.T., Rifkin B.R., and Hauschka P.V. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11 (1990) 309-312
84. Labiner D.M., Ettinger A.B., Fakhoury T.A., et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 50 (2009) 434-442
85. Berent S., Sackellares J.C., Giordani B., et al. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 28 (1987) 61-67
86. Miyamoto T., Kohsaka M., and Tsukasa K. Psychotic episodes during zonisamide treatment. Seizure 9 (2000) 65-70
87. Asanuma M., Miyazaki I., Diaz-Corrales F.J., et al. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinine formation. Neurosci Res 60 (2008) 106-113
88. Loring D.W., Marino S., and Meador K.J. Neuropsychological and behavioural effects of antiepileptic drugs. Neuropsychol Rev 17 (2007) 413-425
89. Herzog A.G., Seibel M.M., Schomer D.L., et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 43 (1986) 341-346
90. Dinesen H., Gram L., Anderson T., et al. Weight gain during treatment with valproate. Acta Neurol Scan 70 (1984) 65-69
91. DeToledo J.C., Toledo C., DeCerce J., et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 19 (1997) 394-396
92. Brodie M.J., Wilson E.A., Wesche D.L., et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine and valproate in patients with partial epilepsy. Epilepsia 46 (2005) 1407-1413
93. Schmidt D., Jacob R., Loiseau P., et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 15 (1993) 67-73
94. Isojärvi J.I., Laatikainen T.J., Pakarinen A.J., et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329 (1993) 1383-1388
95. Isojärvi J.I., Laatikainen T.J., Knip M., et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39 (1996) 579-584
96. Prabhakar S., Sahota P., Kharbanda P.S., et al. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 48 (2007) 1371-1377
97. Kim J.Y., and Lee H.W. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 48 (2007) 1366-1370
98. Luef G., Abraham I., Trinka E., et al. Hyperandrogenism, post-prandial hyperinsulinaemia and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 48 (2002) 91-102
99. Luef G., Abraham I., Haslinger M., et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 249 (2002) 835-841
100. Bauer J., Jarre A., Klingmuller D., et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 41 (2000) 163-167
101. Betts T., Dutton N., and Yarrow H. Epilepsy and the ovary (cutting out the hysteria). Seizure 10 (2001) 220-228
102. Isojärvi J.I., Tauboll E., Pakarinen A.J., et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 111 (2001) 290-296
103. Löfgren E., Mikkonen K., Tolonen U., et al. Reproductive endocrine function in women with epilepsy: The role of epilepsy type and medication. Epilepsy Behav 10 (2007) 77-83
104. Isojärvi J.I., Tauboll E., and Herzog A.G. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 19 (2005) 207-223
105. Patsalos P.N., Zakrewska J.M., and Elyas A.A. Dose dependent enzyme induction by oxcarbazepine. Eur J Clin Pharmacol 39 (1990) 187-188
106. Hitiris N., Barrett J.A., and Brodie M.J. Five case reports: erectile dysfunction association with pregabalin add-on treatment in patients with partial seizures. Epilepsy Behav 8 (2006) 418-421
107. Farhat G., Yamout B., Mikati M.A., et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58 (2002) 1348-1353
108. Souverein P.C., Webb D.J., Weil J.G., et al. Use of antiepileptic drugs and risk of fractures. Case-control study among patients with epilepsy. Neurology 66 (2006) 1318-1324
109. Stephen L.J., McLellan A.R., Harrison J.H., et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 8 (1999) 339-342
110. Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5 Suppl 2 (2004) 3-15
111. Elliot J., Jacobson M., and Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 16 (2007) 22-34
112. Angelopolous A.P., and Goaz P.W. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Oncol 34 (1972) 898-906
113. Falasca G.F., Toly T.M., Reginato A.J., et al. Reflex sympathetic dystrophy associated with antiepileptic drugs. Epilepsia 35 (1994) 394-399
114. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61 (2005) 246-255
115. Valodia P.N., Seymour S.A., McFadyen M.L., et al. Validation of population pharmacokinetic parameters of phenytoin using a parallel Michaelis-Menten and first-order elimination model. Ther Drug Monit 22 (2000) 313-319
116. Back D., Bates M., Bowden A., et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22 (1980) 495-503
117. Fattore C., Cipolla G., Gatti G., et al. Induction of ethinyloestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40 (1999) 783-787
118. Klosterskov Jensen P., Saano V., Haring P., et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 33 (1992) 1149-1152
119. Saano V., Glue P., Banfield C.R., et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 58 (1995) 523-531
120. Rosenfeld W.E., Doose D.R., Walker S.A., et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38 (1997) 317-323
121. Patsalos P.N., Berry D.J., Bourgeois B.F.D., et al. Antiepileptic drugs-best practice guideline for therapeutic drug monitoring. Epilepsia 49 (2008) 1239-1276
122. Pellock J.M. Carbamazepine side effects in children and adults. Epilepsia 28 Suppl 3 (1987) S64-S70
123. O'Brien M.D., and Guillebaud J. Contraception for women with epilepsy. Epilepsia 47 (2006) 1419-1422
124. Johannessen S.I., and Tomson T. General principles. Laboratory monitoring of antiepileptic drugs. In: Levy R.H., Mattson R.H., Meldrum B.S., et al. (Eds). Antiepileptic drugs. 5th edition (2002), Lippincott, Williams and Wilkins, Philadelphia 103-111
125. Scott R.C., Besag F.M., and Neville B.G. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 353 (1999) 623-626
126. Wilson M.T., Macleod S., and O'Regan M.E. Nasal/buccal midazolam use in the community. Arch Dis Child 89 (2004) 50-51
127. International drug price indicator guide. Management sciences for health. 2009. Available at:. http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language =English Accessed April 2009
128. Mohanraj R., and Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 8 (2006) 434-437
129. Annegers J.F., Hauser W.A., and Elveback L.R. Remission of seizures and relapse in patients with epilepsy. Epilepsia 20 (1979) 729-737
130. Devinsky O. Patients with refractory seizures. N Engl J Med 340 (1999) 1565-1570
131. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
132. Cockerell O.C., Johnson A.L., Sander J.W., et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 38 (1997) 31-46
133. Stefan H., Loes da Silva F.H., Löscher W., et al. Epileptogenesis and rational therapeutic strategies. Acta Neurol Scand 113 (2006) 139-155
134. Kwan P., and Brodie M.J. Combination therapy in epilepsy. When and what to use. Drugs 66 (2006) 1817-1829
135. Rowan A.J., Meijer J.W.A., de Beer-Pawlikowski N., et al. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 40 (1983) 797-802
136. Brodie M.J., and Yuen A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate? The 105 Study Group. Epilepsy Res 26 (1997) 423-432
137. Pisani F., Oteri G., Russo M.F., et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40 (1999) 1141-1146
138. Stephen L.J., Sills G.J., and Brodie M.J. Lamotrigine and topiramate may be a useful combination. Lancet 351 (1998) 958-959
139. Peltola J., Peltola M., Raitanen J., et al. Seizure-freedom with combination therapy in localization-related epilepsy. Seizure 17 (2008) 276-280
140. Kwan P., and Brodie M.J. Emerging drugs for epilepsy. Exp Opinion Emerg Drugs 12 (2007) 407-422
141. Meador K., Reynolds M.W., Crean S., et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81 (2008) 1-13
142. Stephen L.J., Kelly K., Mohanraj R., et al. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav 13 (2006) 277-282
143. Stephen L.J., and Brodie M.J. Epilepsy in elderly people. Lancet 355 (2000) 1441-1446
144. Brodie M.J., and Kwan P. Epilepsy in the elderly. Br Med J 331 (2005) 1317-1322
145. Beydoun A., Uthman B.M., Kugler A.R., et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64 (2005) 475-480
146. Pande A.C., Crockatt J.G., Feltner D.E., et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160 (2003) 533-540
147. Michael B., and Marson A.G. Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 2 (2008). CD004154 doi:10.1002/14651858
148. Freynhagen R., Strojek K., Griesing T., et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 (2005) 254-263
149. Serpell M.G. Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 99 (2002) 557-566
150. Ashtari F., Shaygannejad V., and Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 113 (2008) 301-305
151. Privitera M., Fincham R., Penry J., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800- and 1000-mg daily dosages. Neurology 46 (1996) 1678-1682